Published in

Elsevier, Parkinsonism & Related Disorders, (27), p. 81-84

DOI: 10.1016/j.parkreldis.2016.04.016

Links

Tools

Export citation

Search in Google Scholar

Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition

Journal article published in 2016 by Giovanni Cossu ORCID, Roberto Ceravolo ORCID, Maurizio Zibetti ORCID, Roberta Arca, Valeria Ricchi, Alessandra Paribello, Daniela Murgia, Aristide Merola, Alberto Romagnolo, Valentina Nicoletti, Giovanni Palermo, Alessandra Mereu, Leonardo Lopiano, Maurizio Melis, Giovanni Abbruzzese and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Objective: Our purpose was to determine whether the use of catechol-O-methyltransferase-inhibitors (ICOMT) can reduce the risk of developing levodopa (LD)-induced neuropathy in Parkinson's disease (PD) patients. Methods: A multicentre study of 197 PD patients was performed. 144 were exposed to LD for more than three years (LELD group); 53 simultaneously assumed Entacapone for at least eighteen months (LELD_ICOMT group). Results: The prevalence of neuropathy in LELD patients was 19.4% whereas it was 5.7% in LELD_ICOMT group with a significant difference (p = 0.025). In LELD_ICOMT cohort the daily LD dose and serum VB12 levels were significantly higher (p